MX2008009357A - Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. - Google Patents

Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.

Info

Publication number
MX2008009357A
MX2008009357A MX2008009357A MX2008009357A MX2008009357A MX 2008009357 A MX2008009357 A MX 2008009357A MX 2008009357 A MX2008009357 A MX 2008009357A MX 2008009357 A MX2008009357 A MX 2008009357A MX 2008009357 A MX2008009357 A MX 2008009357A
Authority
MX
Mexico
Prior art keywords
composition
solid
taxane
formulation
kit
Prior art date
Application number
MX2008009357A
Other languages
English (en)
Inventor
Antonio Osvaldo Bouzada
Jose Lucio Nunez
Jose Bernardo Iturraspe
De Iturraspe Nora Adriana Moyano
Original Assignee
Eriochem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008009357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eriochem Sa filed Critical Eriochem Sa
Publication of MX2008009357A publication Critical patent/MX2008009357A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

Una composición sólida de taxano (preferentemente docetaxel y paclitaxel) liofilizada, apta para preparar formulaciones farmacéuticas para mamíferos, en particular humanos, que comprende dicho taxano, tensoactivo, excipiente de liofilización y ácido; y además es esencialmente libre de solvente orgánico. Donde dicha composición sólida es libre de polisorbato 80 y de aceite de castor polioxietilado; es estéril; es soluble en soluciones acuosas en ausencia de solvente orgánico; y tienen una densidad aparente de entre 0,05 g/ml y 0,45 g/ml. Un procedimiento de doble liofilización para obtener dicha composición sólida de taxano. Una Formulación farmacéutica de un taxano que comprende dicha composición sólida de taxano liofilizada y una composición solubilizante. Un conjunto que comprende dichas composiciones y una jeringa.
MX2008009357A 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. MX2008009357A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
PCT/ES2007/070013 WO2007082979A1 (es) 2006-01-20 2007-01-19 Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación

Publications (1)

Publication Number Publication Date
MX2008009357A true MX2008009357A (es) 2008-09-10

Family

ID=38134453

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008009358A MX2008009358A (es) 2006-01-20 2007-01-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubllizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
MX2008009357A MX2008009357A (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008009358A MX2008009358A (es) 2006-01-20 2007-01-18 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubllizante de dicha composicion solida de taxano, y un conjunto de elementos (kit

Country Status (15)

Country Link
US (2) US20090215883A1 (es)
EP (2) EP1994925A4 (es)
JP (2) JP2009523770A (es)
AR (1) AR054215A1 (es)
AU (1) AU2007206877A1 (es)
BR (2) BRPI0706931A2 (es)
CA (2) CA2637893A1 (es)
GT (2) GT200800145A (es)
MX (2) MX2008009358A (es)
NZ (2) NZ569783A (es)
PE (2) PE20070945A1 (es)
RU (1) RU2429837C2 (es)
UY (2) UY30100A1 (es)
WO (2) WO2007082978A1 (es)
ZA (2) ZA200805704B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) * 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
CN101160403B (zh) 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
CA2614687C (en) 2005-07-15 2016-03-22 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
CN102026667B (zh) * 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
CA2785926A1 (en) * 2009-12-31 2011-07-07 Mannkind Corporation Injectable formulations for parenteral administration
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
BR112013023062B1 (pt) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
SG11201401921YA (en) 2011-10-31 2014-05-29 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2958554B1 (en) * 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
EP2985038A1 (en) * 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
WO2016090240A1 (en) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CA3026452C (en) 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
KR102490665B1 (ko) 2016-04-04 2023-01-27 크리티테크, 인크. 고형 종양의 치료 방법
RU2708329C2 (ru) * 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
KR20240036128A (ko) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
ES2980123T3 (es) 2017-06-09 2024-09-30 Crititech Inc Composiciones para uso en el tratamiento de quistes epiteliales mediante inyección intraquística de partículas antineoplásicas
KR20210118468A (ko) 2017-06-14 2021-09-30 크리티테크, 인크. 폐 장애의 치료 방법
EP3679925B1 (en) * 2017-09-07 2024-10-23 Shenzhen Salubris Pharmaceuticals Co. Ltd Pharmaceutical composition of docetaxel conjugate and preparation method
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
CN107496352A (zh) * 2017-10-13 2017-12-22 深圳万乐药业有限公司 一种多烯紫杉醇药物组合物及其制备方法
JP7274785B2 (ja) * 2018-07-25 2023-05-17 ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法
AU2019410060A1 (en) 2018-12-21 2021-08-05 Modra Pharmaceuticals B.V. Cancer treatment using docetaxel by controlling peak plasma levels

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IL146659A0 (en) * 1999-05-27 2002-07-25 Acusphere Inc Porous drug matrices and method of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
EP1185248B1 (en) 1999-06-09 2012-05-02 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US20010047162A1 (en) * 2000-02-17 2001-11-29 Yasumi Yugari Injection kit and injection device
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU5887201A (en) * 2000-05-12 2001-11-20 Samyang Corp Method for the preparation of polymeric micelle via phase separation of block copolymer
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US6759539B1 (en) * 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN1850056A (zh) * 2006-03-06 2006-10-25 杨典忠 多西他赛冻干粉针及其制备方法
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano

Also Published As

Publication number Publication date
WO2007082978A1 (es) 2007-07-26
WO2007082979A1 (es) 2007-07-26
CA2637893A1 (en) 2007-07-26
MX2008009358A (es) 2008-09-10
US20090215883A1 (en) 2009-08-27
GT200800145A (es) 2009-07-21
PE20070945A1 (es) 2007-10-07
ZA200805704B (en) 2009-11-25
RU2429837C2 (ru) 2011-09-27
ZA200805989B (en) 2009-05-27
CA2638034A1 (en) 2007-07-26
PE20071243A1 (es) 2008-02-03
NZ569968A (en) 2011-07-29
AU2007206876A1 (en) 2007-07-26
JP2009523771A (ja) 2009-06-25
NZ569783A (en) 2011-04-29
EP1982699A1 (en) 2008-10-22
AR054215A1 (es) 2007-06-13
UY30100A1 (es) 2008-09-02
EP1994925A4 (en) 2013-01-23
UY30099A1 (es) 2008-09-02
WO2007082978B1 (es) 2007-09-07
BRPI0706931A2 (pt) 2011-04-19
JP2009523770A (ja) 2009-06-25
AU2007206877A1 (en) 2007-07-26
BRPI0706932A2 (pt) 2011-04-19
GT200800146A (es) 2008-12-15
US20090215882A1 (en) 2009-08-27
RU2008133761A (ru) 2010-02-27
EP1994925A1 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
ECSP088239A (es) Composición de liberación de fármaco sostenida
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
WO2006110862A3 (en) Micelle composition of polymer and passenger drug
CN1561209A (zh) 含有β－帕拉酮或其衍生物、类似物的药用组合物及其使用方法
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
IN2012DN00407A (es)
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
WO2008127358A3 (en) Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
AR056471A1 (es) Formulaciones de acetato de bazedoxifeno
JPWO2016039433A1 (ja) 新規なヒドロキサム酸誘導体またはその塩を含有する医薬組成物
ATE493127T1 (de) Verwendung von levo-ornidazol zur herstellung eines antiparasitären infektionswirkstoffs
RS106704A (en) Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
WO2007124700A3 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
PE20010407A1 (es) Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa
AR046774A1 (es) Formulacion liofilizada de conjugados de anticuerpos
AR059083A1 (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano
CR10221A (es) Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal